diltiazem has been researched along with Lung Diseases in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 3 (60.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Aquilante, CL; Fish, DN; Kiser, TH; Schoeppler, KE; Zamora, MR | 1 |
Karlsberg, RP | 1 |
Boden, WE; Gibson, RS; Hansen, JF; Messerli, FH; Schechtman, KB | 1 |
Berman, BA; Ross, RN | 1 |
McGoon, MD; Shub, C; Vlietstra, RE | 1 |
3 review(s) available for diltiazem and Lung Diseases
Article | Year |
---|---|
Heart rate-lowering calcium antagonists in hypertensive post-myocardial infarction patients.
Topics: Aged; Calcium Channel Blockers; Diltiazem; Female; Heart Rate; Humans; Hypertension; Lung Diseases; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Randomized Controlled Trials as Topic; Verapamil | 2001 |
Treating coexisting cardiovascular and pulmonary disease with calcium antagonists.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Asthma, Exercise-Induced; Bronchial Spasm; Calcium; Calcium Channel Blockers; Cardiovascular Diseases; Constipation; Diltiazem; Headache; Heart Conduction System; Humans; Ion Channels; Lung Diseases; Lung Diseases, Obstructive; Nifedipine; Verapamil | 1986 |
Selection of optimal drug therapy for the patient with angina pectoris.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Arrhythmias, Cardiac; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 1; Diltiazem; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug Tolerance; Heart Rate; Heart Ventricles; Humans; Hypertension; Kidney Diseases; Lung Diseases; Myocardium; Nifedipine; Nitrates; Physical Exertion; Receptors, Adrenergic, beta; Systole; Vascular Diseases; Vasodilation; Verapamil | 1985 |
2 other study(ies) available for diltiazem and Lung Diseases
Article | Year |
---|---|
The impact of genetic polymorphisms, diltiazem, and demographic variables on everolimus trough concentrations in lung transplant recipients.
Topics: Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; Biomarkers; Cross-Sectional Studies; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Demography; Diltiazem; Everolimus; Female; Follow-Up Studies; Gene Expression Regulation; Genotype; Humans; Immunosuppressive Agents; Lung Diseases; Lung Transplantation; Male; Middle Aged; Polymorphism, Genetic; Pregnane X Receptor; Prognosis; Receptors, Steroid; Sirolimus; Tissue Distribution; Transplant Recipients; Vasodilator Agents | 2014 |
Welcome--the calcium channel blockers.
Topics: Adrenergic beta-Antagonists; Angina Pectoris, Variant; Arrhythmias, Cardiac; Calcium Channel Blockers; Cardiomyopathy, Hypertrophic; Cardiovascular Diseases; Coronary Disease; Diltiazem; Humans; Ion Channels; Lung Diseases; Nifedipine; Tachycardia; Verapamil | 1981 |